WO2009092278A1 - 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 - Google Patents
噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 Download PDFInfo
- Publication number
- WO2009092278A1 WO2009092278A1 PCT/CN2009/000021 CN2009000021W WO2009092278A1 WO 2009092278 A1 WO2009092278 A1 WO 2009092278A1 CN 2009000021 W CN2009000021 W CN 2009000021W WO 2009092278 A1 WO2009092278 A1 WO 2009092278A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thieno
- chlorophenyl
- pyridazine
- carboxamide
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to medicinal chemistry, and in particular to thienopyridazine compounds and processes for their preparation, and pharmaceutical compositions containing them and uses thereof.
- Cancer is a major threat to human health. Most of the human diseases are caused by external environmental factors. The number of people dying of cancer every year in the world is no less than 5 million. Although there are some treatments, such as surgery, radiotherapy, chemotherapy, etc., the patient can be cured, but the cure rate is not high. The prevention and treatment of cancer with chemical drugs is currently one of the most effective methods of subduing tumors.
- Certain compounds of thienooxazinoids or their thiophene analogs exhibit antitumor properties.
- a thienopyridazine compound is disclosed as an IKK inhibitor in WO2005105808 by Hoffmann-La Roche.
- WO2007124181 discloses a thienopyridazine compound as an inhibitor of p38 protease in tyrosine kinases
- a 2-ureido thiophene compound is disclosed in WO 03029241 by Smithldine Beecham, and a 3-ureido thiophene compound similar to the thienoxazine compound as a CHK1 inhibitor is disclosed in WO 03028731.
- a 3-ureidothiophene-improving compound is also disclosed as a CHK1 inhibitor in WO2005066163 to AstraZeneca (Sweden).
- Targets include: VEGFR, EGFR, HER2, SRC, JAK and TEK; and threonine-serine kinase inhibitors, targeting: MEK, JK, c-MET, AKT, PIM, TIE, PLK, etc.
- the compounds described herein are tumors and a class of protein kinase inhibitors, including Checkpoint kinase (CHK1/CHK2).
- the present invention provides a novel thienopyridazine compound as a novel tumor and growth factor-related protein kinase (including CHK1, CHK2) inhibitors, which not only has certain anti-tumor effects, but also enhances other anti-tumor drugs. Anti-tumor efficacy. Summary of the invention
- novel compounds which, in turn, have activity against cell proliferation (e.g., anti-cancer) and are therefore useful in the treatment of humans or animals.
- the invention further relates to methods of preparing the compounds, pharmaceutical compositions comprising the same, and their use in the manufacture of a medicament for producing an anti-cell proliferative effect in a warm-blooded animal such as a human.
- the present invention includes pharmaceutically acceptable salts or prodrugs of such compounds, and in accordance with the present invention, Applicants also provide pharmaceutical compositions and methods of using the compounds to treat cancer.
- cancer solid tumors and leukemia
- fibroproliferative and differentiation diseases include psoriasis, rheumatoid arthritis, Kaposi's Sarcoma, acute and chronic kidney disease, atheroma, atherosclerosis, arterial restenosis, autoimmune disease, acute and chronic inflammation, bone disease and retinal vascular proliferative eye disease.
- R1 and R2 are each independently H or C M thiol
- R3 is a saturated or unsaturated six- or five-membered ring containing N, S or 0, and an optical isomer thereof; and R4 is a monosubstituted or disubstituted halogenated phenyl group at any position.
- R3 is a saturated six-membered ring containing N, S or 0, and optical isomers thereof.
- R3 is hexahydropyridyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyrrolyl, tetrahydrofuranyl, or tetrahydrothiophenyl, and optical isomers thereof.
- R3 is a hexahydropyridyl group, and optical isomers thereof.
- R4 is a monosubstituted halophenyl group.
- R4 is U, wherein X represents F, Cl, Br, I.
- the compound of formula (I) is selected from the group consisting of 2-(4-fluorophenyl)dolad(3-piperidinylmethyl)-thieno[2,3-d]pyridazine-7-carboxamide;
- R3 is pyridinyl, ⁇ -pyranyl, ⁇ -pyranyl, ⁇ -thiopyranyl, ⁇ -thiopyranyl, pyrrolyl, furyl, or thienyl, and optical isomers thereof.
- the compound of formula (I) is selected from the group consisting of: -(4-fluorophenyl)-4-(3-pyridylmethyl)-thieno[2,3-(1]pyridazine-7-carboxamide ; XXXVI-(4-chlorophenyl)-4-(3-pyridylmethyl)-thieno[2,3]pyridazine-7-carboxamide;
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition of the present invention may be administered locally in the form of a solution, a suspension, an aerosol or a dry powder, such as a lung, a head, a colon, etc.; or may be administered systemically, for example, in the form of a tablet or a powder. Oral administration, Alternatively, it can be administered parenterally in the form of a solution or suspension, or subcutaneously, or as a suppository, or transdermally.
- a use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof for the preparation of a medicament for the treatment or prevention of a neoplastic disease comprises cervical cancer, head and neck tumors, breast, ovarian, non-small cell, pancreas, colon, prostate or other tissue cancer, and leukemia and lymphoma, central and peripheral nervous system Tumors as well as other tumors such as melanoma, fibrosarcoma and osteosarcoma.
- the proliferative diseases include autoimmune diseases, inflammation, neurological diseases, and cardiovascular diseases.
- a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate thereof for the manufacture of a medicament for limiting the proliferation of human or animal cells.
- a use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof for the preparation of a medicament for inhibiting tumor and growth factor-related kinase is provided.
- the dosage administered will depend on the compound employed, the mode of administration, the treatment desired, and the condition indicated.
- a process of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate thereof which process comprises: treating a compound of formula A with didecyl oxalate in the presence of a base :
- R is a thiol group of CM, and R1 and R2 are each independently an alkyl group of H or CM; R3 is a saturated or unsaturated six- or five-membered ring containing N, S or 0, and optically different R4 is a monosubstituted or disubstituted halophenyl group at any position.
- the compound of formula A can be prepared by conventional chemical methods known in the art or purchased directly from the market. After obtaining the compound A, a condensation reaction with a dialkyl oxalate such as diethyl oxalate in the presence of a base such as a base LDA (diisopropylamine lithium) commonly used in the synthesis, and a usual organic solvent such as tetrahydrofuran to form a compound Y, The presence of LDA requires that the reaction be carried out at low temperatures. Among them, alkali LDA Those skilled in the art can readily prepare, generally use, and prepare and use at low temperatures.
- a base LDA diisopropylamine lithium
- the R3CH 2 compound bearing a Boc protecting group is prepared by conventional chemical methods known in the art and heated in the presence of a catalyst such as PdCl 2 (dppf), a solvent such as phosphate/1,4-dioxane ( The reaction temperature is 80 to 90 ° C), and the compound of the formula C can be obtained by reacting the compound of the formula C with the R 3 CH 2 compound having a Boc protecting group for a reaction time overnight.
- the compound R3C3 ⁇ 4 needs to be subjected to addition treatment with 9-BBN first, and the Suzuki-Miyaum coupling reaction in Tetrahedron Letters 45 (2004), p6125-6128 is referred to.
- the compound of the formula D is subjected to an aminolysis reaction with the compound HNR1R2 in a sealed environment by a conventional method, and the reaction solvent may be 1,4-dioxane, heated (reaction temperature is 80 ° C), the reaction time is overnight, and then acidic.
- the Boc protecting group on R3 is removed under conditions to provide the acid salt of formula (I), and the pH is adjusted by adding a base to prepare a compound of formula (I).
- the first step the synthesis of 5-bromo-thiophene-3-carboxylic acid
- the third step the synthesis of p-chlorophenylboronic acid
- the liquid phase was re-extracted with 58.8 ml of x2 toluene, and the organic phase was combined and washed with saturated brine to give a neutral color to give a colorless transparent liquid, dried over anhydrous sodium sulfate and filtered. Most of the solvent was evaporated to dryness under reduced pressure to give a white solid.
- the fourth step the synthesis of ethyl 5-(4-chlorophenyl)thiophene-3-carboxylate
- Step 5 Synthesis of ethyl 5-(4-chlorophenyl)-2-ethoxyoxoyl-thiophene-3-carboxylate
- the first step is a first step:
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF and extracted (500ml) with water twice, the combined organic phases with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4 Drying, the solvent was evaporated to give 4-(3-tetrahydropyranylmethyl)-2-(4-chlorophenyl)-thieno[2,3"d]pyridazin-7-carboxylate (25 g).
- the first step is a first step:
- the first step is a first step:
- the first step is a first step:
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(3-tetrahydrofuranmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(3-tetrahydrothiophenemethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- the first step is a first step:
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(3-pyridylmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- DMPU 225 ml
- FeCl 3 (0.75 g)
- CuCl 0.3 g
- Et 2 Zn 106.8 ml
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(3- ⁇ -pyranyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- the first step is a first step:
- 3-bromomethylthiopyran (24.75g, 0.138mol) was added with DMPU (225ml), FeCl 3 (0.75g), CuCl (0.3g), and slowly added dropwise Et 2 Zn (106.8mQ, 40 ⁇ 45°C) The reaction was incubated for 45 min to prepare a zinc reagent.
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give 4-(3- ⁇ -thiolanmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylic acid 1 ester (25 g).
- the first step is a first step:
- the first step is a first step:
- 4-bromomethylpyridine (24.75g, 0.138mol) was added with DMPU (225ml), FeCl 3 (0.75g), CuCl (0.3g), and slowly added Et 2 Zn (10.68ml), 40 ⁇ 45° The incubation reaction was carried out for 45 minutes to prepare a zinc reagent.
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(4-pyridylmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- the first step is a first step:
- DMPU 225 ml
- FeCl 3 (0.75 g)
- CuCl 0.3 g
- Et 2 Zn 106.8 ml
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(3-furanmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- the first step is a first step:
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(3-thienylmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- the second step 4-(3-Thienylmethyl)-2-(4-chlorophenyl)-thieno[2,3-d]U-adazin-7-carboxylic acid ethyl ester (3g), 5ml 1, 4-dioxane
- 5ml of ammonia water to a 25 ml sealed tube, heat, keep the external temperature at 80 ° C, react overnight, the next day, cool to room temperature, transfer the reaction solution to a separatory funnel, add ethyl acetate, shake, and stratify statically.
- the liquid layer was back-extracted twice with ethyl acetate.
- the first step is a first step of the first step.
- reaction solution was poured into saturated saline water, stirred 15min, filtered off with suction, liquid separation, THF was extracted (500ml) with water twice, dried combined organic phases were washed with saturated brine (500mlx3), dried over anhydrous Na 2 S0 4, the solvent was evaporated Dry to give ethyl 4-(2-pyrrolemethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylate (25 g).
- the first step is a first step:
- reaction solution was poured into a saturated saline, 15min, filtration, liquid separation, THF extraction (80ml) the aqueous phase twice, combined organic phases were stirred with saturated brine (80ml> ⁇ 3), dried over anhydrous Na 2 S0 4 Evaporation to give 2-(3,5-dichlorophenyl)-4-(N-Boc-3-piperidinylmethyl)-thieno[2,3-d]pyridazin-7-carboxylic acid ethyl ester (0.5g)
- the compound ⁇ , lactose, sodium carboxymethyl starch and micro-powder silica gel were weighed in a mixing machine for 60 minutes to make them evenly mixed. Then, the prescribed amount of magnesium stearate was added and mixed for 10 minutes, and then discharged, using ordinary gelatin rubber shell. Fill it up.
- dO first administration time
- dn day 17 after administration
- RTV relative tumor volume
- Ip intraperitoneal administration
- GCT is the reference drug: gemcitabine
- ADR is the reference drug: doxorubicin
- CPT-11 is the reference drug: irinotecan
- the compound of the present invention not only has a certain anti-tumor effect, but also enhances the anti-tumor effect of cytotoxic anti-tumor drugs such as gemcitabine, CPT-11, ADR and the like.
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009207968A AU2009207968B2 (en) | 2008-01-08 | 2009-01-07 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses |
US12/811,898 US8962626B2 (en) | 2008-01-08 | 2009-01-07 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses |
CA2711629A CA2711629C (en) | 2008-01-08 | 2009-01-07 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses for treating cancer |
BRPI0907228-4A BRPI0907228B1 (pt) | 2008-01-08 | 2009-01-07 | Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos |
RU2010128221/04A RU2494103C2 (ru) | 2008-01-08 | 2009-01-07 | Соединения тиенопиридазина, их получение, содержащие их фармацевтические композиции, и их применение |
EP09703313A EP2241569B1 (en) | 2008-01-08 | 2009-01-07 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses |
JP2010541010A JP5456694B2 (ja) | 2008-01-08 | 2009-01-07 | チエノピリダジン類化合物、それらの製造方法、医薬組成物及び使用 |
MX2010007502A MX2010007502A (es) | 2008-01-08 | 2009-01-07 | Compuestos de tienopiridazina, sus preparaciones, composiciones farmaceuticas y sus usos. |
KR1020107017631A KR101512530B1 (ko) | 2008-01-08 | 2009-01-07 | 티에노피리다진류 화합물 및 그 제조방법, 약품 조성물 및 그 용도 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810000936.9 | 2008-01-08 | ||
CN200810000936 | 2008-01-08 | ||
CN2009100003371A CN101481380B (zh) | 2008-01-08 | 2009-01-06 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
CN200910000337.1 | 2009-01-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009092278A1 true WO2009092278A1 (zh) | 2009-07-30 |
WO2009092278A8 WO2009092278A8 (zh) | 2010-07-22 |
Family
ID=40878690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000021 WO2009092278A1 (zh) | 2008-01-08 | 2009-01-07 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
Country Status (11)
Country | Link |
---|---|
US (3) | US8318740B2 (zh) |
EP (1) | EP2241569B1 (zh) |
JP (1) | JP5456694B2 (zh) |
KR (1) | KR101512530B1 (zh) |
CN (1) | CN101481380B (zh) |
AU (1) | AU2009207968B2 (zh) |
BR (1) | BRPI0907228B1 (zh) |
CA (1) | CA2711629C (zh) |
MX (1) | MX2010007502A (zh) |
RU (1) | RU2494103C2 (zh) |
WO (1) | WO2009092278A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013505254A (ja) * | 2009-09-18 | 2013-02-14 | ウー,チャングイ | プロテインキナーゼ阻害のための新規化合物及びその治療的使用 |
EP4087563A4 (en) * | 2020-01-07 | 2024-03-27 | Shanghai Huayu Biotechnology Co Ltd | CANCER COMBINATION THERAPY USING A CHK INHIBITOR |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2911926A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
MX2015015416A (es) | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
KR20160005364A (ko) | 2013-05-10 | 2016-01-14 | 님버스 아폴로, 인코포레이티드 | Acc 억제제 및 이의 용도 |
CA2911932A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
MX355943B (es) * | 2013-06-26 | 2018-05-07 | Abbvie Inc | Carboxamidas primarias como inhibidores de btk. |
CN103288614B (zh) * | 2013-06-27 | 2014-09-17 | 中国科学院昆明植物研究所 | 具有抗肿瘤活性的间苯三酚类化合物及其药物组合物 |
CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
CN103694217A (zh) * | 2013-12-20 | 2014-04-02 | 华东师范大学 | 一种2,4-二取代噻吩衍生物及其制备方法和应用 |
WO2021208055A1 (zh) * | 2020-04-17 | 2021-10-21 | 浙江医药股份有限公司新昌制药厂 | 一种噻吩并哒嗪类化合物的晶型及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016909A1 (en) * | 2003-08-15 | 2005-02-24 | Astrazeneca Ab | Substituted thiophenes and uses thereof |
WO2005066163A2 (en) * | 2004-01-05 | 2005-07-21 | Astrazeneca Ab | Thiophene derivatives as chk 1 inihibitors |
WO2005105808A1 (en) * | 2004-05-04 | 2005-11-10 | F. Hoffman-La Roche Ag | Thienopyridazines as ikk inhibitors |
WO2006106326A1 (en) * | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2000000070A (es) * | 1999-09-28 | 2002-02-28 | Bayer Healthcare Llc | Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis |
US7745449B2 (en) * | 2006-04-21 | 2010-06-29 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
CN101687882A (zh) * | 2007-04-25 | 2010-03-31 | 百时美施贵宝公司 | 非碱性黑色素浓集激素受体-1拮抗剂 |
WO2009003911A1 (en) * | 2007-06-29 | 2009-01-08 | 4Sc Ag | Thiophene-imidazopyridines |
-
2009
- 2009-01-06 CN CN2009100003371A patent/CN101481380B/zh active Active
- 2009-01-07 WO PCT/CN2009/000021 patent/WO2009092278A1/zh active Application Filing
- 2009-01-07 EP EP09703313A patent/EP2241569B1/en active Active
- 2009-01-07 JP JP2010541010A patent/JP5456694B2/ja active Active
- 2009-01-07 RU RU2010128221/04A patent/RU2494103C2/ru active
- 2009-01-07 US US12/349,888 patent/US8318740B2/en active Active
- 2009-01-07 BR BRPI0907228-4A patent/BRPI0907228B1/pt active IP Right Grant
- 2009-01-07 CA CA2711629A patent/CA2711629C/en active Active
- 2009-01-07 AU AU2009207968A patent/AU2009207968B2/en active Active
- 2009-01-07 KR KR1020107017631A patent/KR101512530B1/ko active IP Right Grant
- 2009-01-07 US US12/811,898 patent/US8962626B2/en active Active
- 2009-01-07 MX MX2010007502A patent/MX2010007502A/es active IP Right Grant
-
2012
- 2012-11-02 US US13/668,197 patent/US9249154B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016909A1 (en) * | 2003-08-15 | 2005-02-24 | Astrazeneca Ab | Substituted thiophenes and uses thereof |
WO2005066163A2 (en) * | 2004-01-05 | 2005-07-21 | Astrazeneca Ab | Thiophene derivatives as chk 1 inihibitors |
WO2005105808A1 (en) * | 2004-05-04 | 2005-11-10 | F. Hoffman-La Roche Ag | Thienopyridazines as ikk inhibitors |
WO2006106326A1 (en) * | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013505254A (ja) * | 2009-09-18 | 2013-02-14 | ウー,チャングイ | プロテインキナーゼ阻害のための新規化合物及びその治療的使用 |
US9487539B2 (en) | 2009-09-18 | 2016-11-08 | Zhanggui Wu | Compounds and therapeutic use thereof for protein kinase inhibition |
EP4087563A4 (en) * | 2020-01-07 | 2024-03-27 | Shanghai Huayu Biotechnology Co Ltd | CANCER COMBINATION THERAPY USING A CHK INHIBITOR |
Also Published As
Publication number | Publication date |
---|---|
BRPI0907228A2 (pt) | 2015-07-14 |
US20130143887A1 (en) | 2013-06-06 |
RU2010128221A (ru) | 2012-02-20 |
CA2711629C (en) | 2017-10-24 |
BRPI0907228B1 (pt) | 2021-08-03 |
AU2009207968B2 (en) | 2014-04-24 |
US20110009415A1 (en) | 2011-01-13 |
AU2009207968A1 (en) | 2009-07-30 |
KR101512530B1 (ko) | 2015-04-15 |
CN101481380A (zh) | 2009-07-15 |
EP2241569A4 (en) | 2011-01-12 |
WO2009092278A8 (zh) | 2010-07-22 |
RU2494103C2 (ru) | 2013-09-27 |
CA2711629A1 (en) | 2009-07-30 |
US8962626B2 (en) | 2015-02-24 |
US9249154B2 (en) | 2016-02-02 |
CN101481380B (zh) | 2012-10-17 |
US8318740B2 (en) | 2012-11-27 |
EP2241569A1 (en) | 2010-10-20 |
US20090275585A1 (en) | 2009-11-05 |
KR20100117069A (ko) | 2010-11-02 |
EP2241569B1 (en) | 2012-05-23 |
JP2011508750A (ja) | 2011-03-17 |
JP5456694B2 (ja) | 2014-04-02 |
MX2010007502A (es) | 2010-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009092278A1 (zh) | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 | |
CA2953132C (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
TWI787018B (zh) | 轉染過程重排之抑制劑 | |
CN103717574B (zh) | 用于抑制nampt的新化合物和组合物 | |
TW200526639A (en) | Pyrazole derivatives and uses thereof | |
CN104003940B (zh) | 2,4‑二氟‑5‑(酞嗪酮‑1‑甲基)‑苯甲酰哌嗪类化合物及其用途 | |
JP2009102447A (ja) | 置換3−アミノ−チエノ[2,3−b]ピリジン−2−カルボン酸アミド化合物、その製造方法及び使用 | |
CN106986863A (zh) | Dna‑pk抑制剂 | |
JP2017512783A (ja) | ピペリジン−ジオン誘導体 | |
TW200536849A (en) | Substituted heterocycles and the uses thereof | |
CN101479274A (zh) | 药用化合物 | |
CN105408320A (zh) | 用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物 | |
EA020302B1 (ru) | Новые азагетероциклические соединения | |
JP2010522238A (ja) | Ikk2阻害剤としてのインドールカルボキサミド | |
CN101395136A (zh) | 新的吡啶-3-胺衍生物 | |
JP7239246B2 (ja) | アンドロゲン受容体調節因子及びグルココルチコイド受容体調節因子としての新規アナログ | |
CN109824690A (zh) | Mcl-1选择性抑制剂及其制备和用途 | |
TW202214631A (zh) | 作為Akt激酶抑制劑的化合物 | |
TW202211917A (zh) | 對***素e2受體具有抑制活性的新穎化合物及其用途 | |
CN113493433B (zh) | 一种可作为gpr35受体激动剂的苯并吡喃酮衍生物、制备方法及其应用 | |
TW202345793A (zh) | 包含抑制***素e2受體之新穎化合物與抗癌藥物的用於治療癌症之藥學組成物 | |
CN114702488A (zh) | 稠环酰胺类化合物,其药物组合物、制备方法和应用 | |
CN102344443A (zh) | 点击化学合成开环马来酰亚胺类化合物及其在治疗疾病中的应用 | |
WO2009085040A1 (en) | Protein kinase inhibitors | |
WO2018199797A1 (ru) | Замещенные 2-метилиден-5-(фениламино)-2,3-дигидротиофен-3-оны для лечения лейкозов с транслокациями mll-гена и других онкологических заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09703313 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010541010 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2711629 Country of ref document: CA Ref document number: MX/A/2010/007502 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009703313 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5571/DELNP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20107017631 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010128221 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009207968 Country of ref document: AU Date of ref document: 20090107 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12811898 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0907228 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100707 |